Royalties payable Royalties Payable Represents the amount of royalties payable. Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Current year expected contributions total Defined Benefit Plan, Expected Future Employer Contributions, Current Fiscal Year Statistical Measurement [Domain] Statistical Measurement [Domain] Schedule of Marketable Securities Portfolio Debt Securities, Available-for-Sale [Table Text Block] Projected cash flows period (in years) Fair Value Inputs Cash Flows Estimated Period Period of time used to measure cash flows to find the present value of an amount to be paid or received in the future as an input to measure fair value. Anti-dilutive securities Earnings Per Share, Diluted, Other Disclosure [Abstract] Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Award Timing Predetermined Award Timing Predetermined [Flag] Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Entity File Number Entity File Number Additional Paid-in Capital Additional Paid-in Capital [Member] Tabular List, Table Tabular List [Table Text Block] Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units and performance shares, net of shares withheld for taxes and shares of Common Stock under the ESPP Stock Issued During Period, Value, Stock Options And Restricted Stock Units Exercised And Employee Stock Purchase Plan Value stock issued during the period as a result of the exercise of stock options and restricted stock units and the aggregate change in value for stock issued during the period as a result of employee stock purchase plan. Basic Net Income (Loss) Per Share Earnings Per Share, Basic [Abstract] Recent Accounting Pronouncements and Regulatory Updates New Accounting Pronouncements, Policy [Policy Text Block] Accounts payable Increase (Decrease) in Accounts Payable Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate (SOFR) [Member] Share repurchase program, tender offer (in dollars per share) Share Repurchase Program, Tender Offer, Share Price Share Repurchase Program, Tender Offer, Share Price Downtown Wilmington Downtown Wilmington [Member] Downtown Wilmington Share-Based Payment Arrangement Share-Based Payment Arrangement [Member] Released (in shares) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Released In Period Represents the number of shares of employee compensation programs, other than options, released during the period. Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Share repurchase, fees and expenses Share Repurchase, Fees and Expenses Share Repurchase, Fees and Expenses Measurement Basis [Axis] Measurement Basis [Axis] Basic (in USD per share) Basic net income (loss) per share ( in USD per share) Earnings Per Share, Basic Adjustment to Compensation: Adjustment to Compensation [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Revenues Revenue from Contract with Customer [Text Block] Operating lease right-of-use assets Operating lease right-of-use assets Contractual agreement that stipulates the lessee pay the lessor for use of an asset under operating lease. Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Schedule of Segment Reporting Information, by Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Upfront payment under license agreement License Agreement Upfront Payment Amount Paid Represents the amount of the upfront payment made under the license agreement. Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Issuance of shares of Common Stock under the ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Investment in Syndax Investment in Syndax [Member] Represents investment information pertaining to Syndax Pharmaceuticals Inc. Measurement Input Type [Domain] Measurement Input Type [Domain] Adjustment to Compensation, Amount Adjustment to Compensation Amount Percentage of concentration risk Concentration Risk, Percentage Principles of Consolidation Consolidation, Policy [Policy Text Block] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Schedule of Inventory Schedule of Inventory [Table Text Block] Tabular disclosure of carrying amount of inventories as of the balance sheet date. Share-based Payment Arrangement, Option Employee Stock Options Share-Based Payment Arrangement, Option [Member] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Share repurchase, excise tax Share Repurchase Program, Excise Tax Antidilutive Securities [Axis] Antidilutive Securities [Axis] Total stockholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Other comprehensive (loss) income before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Measurement Frequency [Axis] Measurement Frequency [Axis] Insider Trading Policies and Procedures [Line Items] Stock compensation expense Share-Based Payment Arrangement, Expense Schedule of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Current assets: Assets, Current [Abstract] Options cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Number of shares awarded for each RSU (in shares) Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Per Restricted Stock Units Represents the number of shares awarded for each restricted share units. Total liabilities and stockholders’ equity Liabilities and Equity Fair Value, Recurring Fair Value, Recurring [Member] Defined Benefit Pension Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Cover [Abstract] Cover [Abstract] Net amount reclassified from accumulated other comprehensive loss Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Schedule of RSU Award and PSU Activity Under the 2010 Stock Plan Schedule of RSU award and PSU activity under the 2010 Stock Plan [Table Text Block] Tabular disclosure represents the schedule of share based compensation other than stock options activity. Maximum Maximum [Member] Decrease in royalties payable Increase (Decrease) in Royalties Payable Excise tax paid on repurchase of Common Stock Payments For Repurchase Of Common Stock, Excise Tax Payments For Repurchase Of Common Stock, Excise Tax Accounting Policies [Abstract] Accounting Policies [Abstract] Acquisitions Asset Acquisition [Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Concentration of Credit Risk and Current Expected Credit Losses Concentration Risk Disclosure [Text Block] Payment of contingent consideration Payment of Contingent Consideration The cash outflow with regard to the contingent consideration during the period. Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Pay vs Performance Disclosure [Line Items] Share Repurchase Program [Line Items] Share Repurchase Program [Line Items] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Foreign currency translation gain (loss) Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Customer D Customer D [Member] Represents information pertaining to the customer D. Issuance of shares of Common Stock for services rendered (in shares) Stock Issued During Period, Shares, Issued for Services Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Total liabilities Financial Liabilities Fair Value Disclosure Developmental and Regulatory Milestones Developmental And Regulatory Milestones [Member] Developmental And Regulatory Milestones Income before provision for income taxes Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Entity Shell Company Entity Shell Company Clinical related costs Accrued Clinical Related Costs Current Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical related costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Other liabilities Other Liabilities, Noncurrent Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Other intangible assets, net Other Intangible Assets, Net Company Selected Measure Amount Company Selected Measure Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Measurement Input Type [Axis] Measurement Input Type [Axis] Name Measure Name Less than 1 Year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Operating lease liabilities Operating Lease, Liability, Current Schedule of Roll Forward of Level 3 Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Herve Hoppenot [Member] Herve Hoppenot Additional milestone payments under the license agreement License Agreement Additional Milestone Payments Represents the additional milestone payments to be made under the license agreement. Award Timing Method Award Timing Method [Text Block] Litigation Case [Domain] Litigation Case [Domain] Total inventory Inventory Net Current and Noncurrent Represents the aggregate carrying amount of current and noncurrent portion, net of valuation reserves and allowances, as of the balance sheet date of inventories. Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss Award Type [Axis] Award Type [Axis] Foreign Currency Translation Gains (Loss) Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Legal Entity [Axis] Legal Entity [Axis] Total assets Assets Investment, Name [Domain] Investment, Name [Domain] Trading Symbol Trading Symbol Geographical [Domain] Geographical [Domain] Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units, net of shares withheld for taxes (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Accrued and other liabilities Accrued Liabilities and Other Liabilities Entity Address, City or Town Entity Address, City or Town Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Organization and Business Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Other segment items Segment Reporting, Other Segment Item, Amount Xencor Xencor [Member] Xencor Effect of exchange rates on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Concentration Risk Type [Axis] Concentration Risk Type [Axis] Inventory Inventory Disclosure [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Upfront and immediate milestone payment to be received under license agreement License Agreement, Upfront Payment and Immediate Milestone Payment to be Received Represents the upfront and immediate milestone payment received under the license agreement. Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Property, plant, and equipment, capitalized Property, Plant and Equipment, Additions Royalty rate payable, percent reduction (as a percent) Royalty Rate Payable, Percent Reduction Royalty Rate Payable, Percent Reduction Entity Emerging Growth Company Entity Emerging Growth Company Payments for intangible assets Payments to Acquire Intangible Assets Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Leased assets obtained in exchange for new operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Options, RSUs and PSUs granted and issuance of shares for services rendered (in shares) Share Based Compensation Arrangement by Share Based Payment Award, Number of Shares Granted Number of shares granted under an established share-based compensation plan. Summary of marketable security portfolio Debt Securities, Available-for-Sale [Line Items] Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Deferred tax asset Asset Acquisition, Deferred Tax Asset Asset Acquisition, Deferred Tax Asset Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Lee Heeson [Member] Lee Heeson Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Business Combination [Domain] Business Combination [Domain] Novartis and Lilly Novartis And Lilly [Member] Represents information pertaining to both the Collaboration partners Novartis And Lilly Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Plan Name [Axis] Plan Name [Axis] PEO PEO [Member] Schedule of Disaggregated Revenue Disaggregation of Revenue [Table Text Block] Interest income Investment Income, Interest Research and development - external Research And Development Expense, External Research And Development Expense, External Accrued taxes Accrued Income Taxes, Current United States UNITED STATES Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Mohamed Issa [Member] Mohamed Issa Volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Retained Earnings (Accumulated Deficit) Retained Earnings [Member] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current RSU and PSU Activity Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Schedule of Accrued and Other Current Liabilities Schedule of Accrued Liabilities [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Restatement Determination Date Restatement Determination Date Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Income Statement [Abstract] Income Statement [Abstract] Provision for income taxes Income Tax Expense (Benefit) Interest rate margin (as percent) Debt Instrument, Basis Spread on Variable Rate Purchases of marketable securities Payments to Acquire Marketable Securities Sale of Stock [Domain] Sale of Stock [Domain] Thomas Tray [Member] Thomas Tray Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Product and Service [Domain] Product and Service [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Property and equipment, gross Property, Plant and Equipment, Gross Syndax Syndax Represents member information pertaining to Syndax Pharmaceuticals Inc. Net income (loss) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Capital expenditures Payments to Acquire Other Productive Assets Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] City Area Code City Area Code Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] All Trading Arrangements All Trading Arrangements [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Schedule of Valuation Assumptions Used for Valuation of Fair Value of Stock Compensation Granted Schedule of Share Based Payment Award, Stock Options and Employee Stock Purchase Plan Valuation Assumptions [Table Text Block] Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock options plan and employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. Contract dispute settlement Contract dispute settlement Gain (Loss) from Litigation Settlement Accrued and other current liabilities Total accrued and other current liabilities Accrued Liabilities, Current JAKAVI JAKAVI Represents information pertaining to JAKAVI (ruxolitinib), an oral Janus associate kinase (JAK) inhibitor sold outside the United State of America. Payments made during the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Debt Securities, Trading, and Equity Securities, FV-NI [Table] Debt Securities, Trading, and Equity Securities, FV-NI [Table] General and administrative General and Administrative Expense Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Revenue, Product and Service Benchmark Revenue, Product and Service Benchmark [Member] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Net cash provided by (used in) operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Stock Incentive Plan 2010 Stock Incentive Plan 2010 [Member] Stock Incentive Plan 2010 Effective Income Tax Rate Reconciliation [Table] Effective Income Tax Rate Reconciliation [Table] Fair Value Total Debt Securities, Available-for-Sale, Excluding Accrued Interest Preferred stock, par value (in USD per share) Preferred Stock, Par or Stated Value Per Share Revenues from External Customers and Long-Lived Assets [Line Items] Revenues from External Customers and Long-Lived Assets [Line Items] Subsequent Event Subsequent Event [Member] Debt instrument, credit spread adjustment on variable rate (as percent) Debt Instrument, Credit Spread Adjustment On Variable Rate Debt Instrument, Credit Spread Adjustment On Variable Rate Effective Income Tax Rate Reconciliation [Line Items] Effective Income Tax Rate Reconciliation [Line Items] Selling, General and Administrative Expenses Selling, General and Administrative Expenses [Member] Cost of Sales Cost of Sales [Member] Goodwill Goodwill Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] GVHD GVHD [Member] Represents information pertaining to GVHD, an Graft-Versus-Host Disease field. PEO Total Compensation Amount PEO Total Compensation Amount Increase in maximum revolving commitments Line of Credit Facility, Additional Borrowing Capacity Line of Credit Facility, Additional Borrowing Capacity In Process Research and Development - INCB000262 In Process Research and Development - INCB000262 [Member] In Process Research and Development - INCB000262 Research and development - internal Research And Development Expense, Internal Research And Development Expense, Internal Equity Components [Axis] Equity Components [Axis] Property and equipment, net Property, Plant and Equipment [Line Items] Issuance of shares of Common Stock for services rendered Stock Issued During Period, Value, Issued for Services Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Concentration Risk [Table] Concentration Risk [Table] Dutch Auction Tender Offer Dutch Auction Tender Offer [Member] Dutch Auction Tender Offer Product revenues, net Product [Member] Number of reportable segments Number of Reportable Segments Laboratory equipment Equipment [Member] Valuation input (as a percent) Business Combination, Contingent Consideration, Liability, Measurement Input Weighted-average fair value assumptions Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Additional PSUs earned (in USD per share) Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Other, Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement By Share-Based Payment Award, Non-Option Equity Instruments, Other, Weighted Average Grant Date Fair Value Supplemental Schedule of Cash Flow Information Supplemental Cash Flow Information [Abstract] Other Performance Measure, Amount Other Performance Measure, Amount Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Inventory [Line Items] Inventory [Line Items] Entity Address, State or Province Entity Address, State or Province Payment of finance lease liabilities Finance Lease, Principal Payments ICLUSIG ICLUSIG [Member] Represents information pertaining to ICLUSIG, a kinase inhibitor. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Total current liabilities Liabilities, Current Credit Concentration Risk Credit Concentration Risk [Member] Number of independent programs License Agreement, Maximum Number Of Independent Programs Represents the maximum number of independent programs encompassed under the collaboration agreement. Gain (loss) on equity investments (Gain) on equity investments Equity Securities, FV-NI, Gain (Loss) Individual: Individual [Axis] Defined contribution expense Defined Contribution Plan, Cost Vesting [Axis] Vesting [Axis] Leased assets obtained in exchange for new finance lease liabilities Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Research and Development Expense Research and Development Expense [Member] Additional paid-in capital Additional Paid in Capital, Common Stock Sales and marketing Accrued Marketing Costs, Current Entity [Domain] Entity [Domain] Net cash (used in) provided by investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Document Fiscal Year Focus Document Fiscal Year Focus ARIAD ARIAD Represents information pertaining to ARIAD Pharmaceuticals. Basis of presentation Basis of Accounting, Policy [Policy Text Block] Achievement of Milestone [Domain] Achievement of Milestone [Domain] Different categories of achievement of milestones. Sale of equity investments Proceeds from Sale of Long-Term Investments Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Ownership percentage (as a percent) Subsidiary, Ownership Percentage, Noncontrolling Owner Baker Entities Baker Entities [Member] Baker Entities Effective tax rate Effective Income Tax Rate Reconciliation, Percent Prepaid expenses and other current assets Asset Acquisition, Prepaid Expenses And Other Current Assets Asset Acquisition, Prepaid Expenses And Other Current Assets In Process Research and Development - INCB000547 In Process Research and Development - INCB000547 [Member] In Process Research and Development - INCB000547 Entity Interactive Data Current Entity Interactive Data Current Plan Name [Domain] Plan Name [Domain] Vesting period of recognition of the unrecognized compensation cost of nonvested awards (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Options exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Advance written notice period (in days) License Agreement, Advance Written Notice Period License Agreement, Advance Written Notice Period Payment obligation breach, written notice period (in days) License Agreement, Written Notice Period For Payment Obligation Breach, License Agreement, Written Notice Period For Payment Obligation Breach Segment Information Segment Reporting Disclosure [Text Block] Non-current liabilities Asset Acquisition, Noncurrent Liabilities Asset Acquisition, Noncurrent Liabilities Fair value of financial instruments Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Ownership [Domain] Ownership [Domain] Schedule of Net Periodic Benefit Cost Schedule of Net Benefit Costs [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Acquisition-related contingent consideration Business Combination, Contingent Consideration, Liability Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Commercialization Milestones Commercialization Milestones Represents information pertaining to certain commercialized events on the basis of which certain milestones are achieved. Selling, general and administrative Selling, General and Administrative Expense Deferred income tax asset Deferred Income Tax Assets, Net Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Depreciation and amortization Depreciation, Depletion and Amortization Other assets, net Other Assets, Noncurrent Royalties Accrued Royalties, Current Customer [Domain] Customer [Domain] Entity Central Index Key Entity Central Index Key PEO Name PEO Name Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount OLUMIANT OLUMIANT [Member] Baricitinib for the treatment of moderate-to-severe rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs). Revolving Credit Facility Revolving Credit Facility [Member] Balance at the beginning of the period Balance at the end of the period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Upfront payment received under license agreement License Agreement, Upfront Payment Received Represents the upfront payment received under the license agreement. Acquisition-related contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Arrangement Duration Trading Arrangement Duration Share-based Payment Arrangement, Tranche One Share-Based Payment Arrangement, Tranche One [Member] Customer A, B, C, D, E and F Customer A, B, C, D, E And F [Member] Customer A, B, C, D, E And F Computer equipment Computer Equipment [Member] Segments [Axis] Segments [Axis] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets API and Work-in-process Inventory, Work in Process, Net of Reserves Exercise Price Award Exercise Price Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Entity Filer Category Entity Filer Category Additional PSUs earned (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Other Local Phone Number Local Phone Number Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Europe Europe [Member] Statement [Table] Inventory, Current [Table] Subsequent Event Type Subsequent Event Type [Axis] Stock Compensation Share-Based Payment Arrangement [Text Block] Liability Liability [Member] Acquisition-related contingent consideration Business Combination, Contingent Consideration, Liability, Current Total U.S. GAAP Consideration (net of compensation expense) Asset Acquisition, Assets Acquired and Liabilities Assumed, Net Asset Acquisition, Assets Acquired and Liabilities Assumed, Net Incyte Incyte [Member] Represents member information pertaining to Incyte. ASSETS Assets [Abstract] Other countries Other Countries [Member] Other Countries Credit Facility [Axis] Credit Facility [Axis] Inventory Inventories-noncurrent Inventory, Noncurrent Available Shares for Grant Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Marketable securities-amortized cost Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss, Current Vesting [Domain] Vesting [Domain] Period of lower average per unit cost of materials (in months) Period Of Deviation From Average, Cost Of Goods Sold Represents the length of time in which cost of goods sold will deviate from average due to unusual and/or infrequent conditions. Cancelled (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Employee Benefit Plans Retirement Benefits [Text Block] Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Credit Facility [Domain] Credit Facility [Domain] Stockholders’ equity: Equity, Attributable to Parent [Abstract] Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Percentage of units vesting at the end of each calendar year (as a percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Entity Address, Address Line One Entity Address, Address Line One Agenus Agenus Represents details pertaining to Agenus with whom we have entered into a License, Development and Commercialization Agreement. Research and development Research and Development Expense Accumulated Other Comprehensive (Loss) Income AOCI Attributable to Parent [Member] Investment, Name [Axis] Investment, Name [Axis] Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] Ownership [Axis] Ownership [Axis] Amortization of prior service cost Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Building and leasehold improvements Building and leasehold improvements Represents information relating to building and leasehold improvements. Fair Value as of Grant Date Award Grant Date Fair Value Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Accounts receivable Accounts Receivable, after Allowance for Credit Loss Entity Registrant Name Entity Registrant Name Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Unpaid excise tax on repurchase of Common Stock Excise Tax On Repurchase Of Common Stock Incurred But Not Yet Paid Excise Tax On Repurchase Of Common Stock Incurred But Not Yet Paid Dilutive stock options and awards ( in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Total costs, expenses and other Costs and Expenses Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Unrecognized compensation cost for nonvested option (in USD per share) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount License Agreements Related Party Transaction [Line Items] Document Quarterly Report Document Quarterly Report Total assets Assets, Fair Value Disclosure Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Customer C Customer C [Member] Represents information pertaining to the customer C. Payments for asset acquisitions Payments For Asset Acquisitions Payments For Asset Acquisitions Counterparty Name [Domain] Counterparty Name [Domain] Debt securities (government) Debt securities (government) Debt securities issued by government or corporate business, banks and other entities with a promise of repayment. U.S. Centers for Medicare and Medicaid Services U.S. Centers for Medicare and Medicaid Services [Member] U.S. Centers for Medicare and Medicaid Services Number of operating segments Number of Operating Segments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Interest cost Defined Benefit Plan, Interest Cost Granted (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Title Trading Arrangement, Individual Title Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Restatement Determination Date: Restatement Determination Date [Axis] Other non-current assets Asset Acquisition, Other Non Current Assets Asset Acquisition, Other Non Current Assets Issuance of shares of Common Stock upon exercise of stock options and settlement of employee restricted stock units, net of shares withheld for taxes Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Non-PEO NEO Non-PEO NEO [Member] Accounts Receivable Accounts Receivable [Member] Marketable securities-allowance for credit losses Debt Securities, Available-for-Sale, Allowance for Credit Loss Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Board of Directors Approved Share Repurchase Program Board Of Directors Approved Share Repurchase Program [Member] Board Of Directors Approved Share Repurchase Program Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Schedule of Fair Value of Liabilities Measured on Recurring Basis Fair Value, Liabilities Measured on Recurring Basis [Table Text Block] Sale of Stock [Axis] Sale of Stock [Axis] Land Land [Member] Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Name Trading Arrangement, Individual Name Options, RSUs and PSUs cancelled (in shares) Share Based Compensation Arrangement by Share Based Payment Award, Number of Shares Canceled Number of shares canceled under an established share-based compensation plan. Award Type [Domain] Award Type [Domain] Equity Awards Adjustments Equity Awards Adjustments [Member] Other, net Other Noncash Income (Expense) Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Revenues Disaggregation of Revenue [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Switzerland SWITZERLAND Dividend yield (as percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Estimate of Fair Value Measurement Estimate of Fair Value Measurement [Member] Share Repurchase Program [Axis] Share Repurchase Program [Axis] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Michael Morrissey [Member] Michael Morrissey Name Awards Close in Time to MNPI Disclosures, Individual Name AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Asset acquisition, consideration transferred, transaction cost Asset Acquisition, Consideration Transferred, Transaction Cost Accrued and Other Current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Grant date value of shares outstanding at the beginning of the period (in USD per share) Grant date value of shares at the end of the period (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Restricted cash Restricted Cash, Noncurrent JAKAVI JAKAVI [Member] Represents information pertaining to JAKAVI (ruxolitinib), an oral Janus associate kinase (JAK) inhibitor sold outside the United State of America. (Gain) loss on change in fair value of acquisition-related contingent consideration Loss on change in fair value of acquisition-related contingent consideration (Gain) loss on change in fair value of acquisition-related contingent consideration Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Employee Stock Purchase Plan Employee Stock [Member] Asset acquisition, compensation expense Asset Acquisition, Compensation Expense Asset Acquisition, Compensation Expense Milestone payment made under license agreement License Agreement Milestone Payment Amount Paid Represents the amount of the milestone payment made under the license agreement. Asset Acquisition [Line Items] Asset Acquisition [Line Items] Revenues: Revenues [Abstract] Accrued and Other Current Liabilities Accrued And Other Current Liabilities [Member] Primary financial statement caption encompassing accrued and other current liabilities. Inventory incurred prior to FDA approval Inventory, Recorded as Research and Development Expense Represents the aggregate carrying amount of current and noncurrent portion, net of valuation reserves and allowances, as of the balance sheet date of inventories recorded as research and development expense. Other product royalty revenues Other Product Royalty Revenues [Member] Other Product Royalty Revenues Stock compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Sales and marketing Selling and Marketing Expense Financial Instruments [Domain] Financial Instruments [Domain] Litigation Case [Axis] Litigation Case [Axis] Liability Class [Axis] Liability Class [Axis] Milestone and contract revenues Milestone And Contract Revenues [Member] Represents information pertaining to milestone revenue. Segments [Domain] Segments [Domain] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Performance Shares Performance Shares [Member] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Product royalty revenues Royalty [Member] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Non-deductible charges Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Inventory Increase (Decrease) in Inventories Inventory Inventories - current Inventory, Net Minimum Minimum [Member] Net Unrealized Gains (Losses) on Marketable Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Company Selected Measure Name Company Selected Measure Name Fair Value Measurement [Domain] Fair Value Measurement [Domain] Released (in USD per share) Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Released In Period, Weighted Average Grant Date Fair Value Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Released In Period, Weighted Average Grant Date Fair Value Preferred Stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding Preferred Stock, Value, Issued Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Accounts payable Accounts Payable, Current PEMAZYRE PEMAZYRE [Member] Represents information pertaining to PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor (FGFR) inhibitor, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test. Proceeds from issuance of Common Stock under stock plans Proceeds from Stock Plans Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Diluted net income (loss) Net Income (Loss) Available to Common Stockholders, Diluted All Executive Categories All Executive Categories [Member] Text Block [Abstract] Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Finished goods Inventory, Finished Goods, Net of Reserves Common Stock, $0.001 par value; 400,000,000 shares authorized; 196,130,993 and 193,434,305 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively Common Stock, Value, Issued Expiration period (in years) License Agreement, Royalty Obligation Expiration Period License Agreement, Royalty Obligation Expiration Period Finance lease right-of-use assets, net Finance Lease, Right-of-Use Asset, after Accumulated Amortization Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Share-based Payment Arrangement, Tranche Two Share-Based Payment Arrangement, Tranche Two [Member] Diluted (in shares) Weighted average shares used to compute diluted net income (loss) per share ( in shares) Weighted Average Number of Shares Outstanding, Diluted Commitments and contingencies (Note 17) Commitments and Contingencies Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] OLUMIANT Royalty Revenues OLUMIANT Royalty Revenues [Member] Represents information pertaining to OLUMIANT royalty revenues, a treatment of adults with moderately-to-severely active rheumatoid arthritis. Business Combination [Axis] Business Combination [Axis] TABRECTA Royalty Revenues TABRECTA Royalty Revenues [Member] Represents information pertaining to TABRECTA royalty revenues, treatment of adult patients with metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping (METex14). Entity Small Business Entity Small Business Schedule of Revenue from External Customers by Geographic Areas Revenue from External Customers by Geographic Areas [Table Text Block] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Schedule of Shares Available for Grant Schedule of Nonvested Share Activity [Table Text Block] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Document Transition Report Document Transition Report Contingent consideration earned during the period but not yet paid Contingent consideration earned during the period but not yet paid Business Combination, Contingent Consideration Arrangements, Change In Amount Of Contingent Consideration Liability, Consideration Earned Amount of decrease in the value of a contingent consideration liability attributable to consideration earned by the acquiree in a business combination. 1-5 Years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Development and Regulatory Milestones Development and Regulatory Milestones Represents information pertaining to certain development and regulatory events on the basis of which certain milestones are achieved. Underlying Securities Award Underlying Securities Amount Concentration of risk Concentration Risk [Line Items] Equity Component [Domain] Equity Component [Domain] JAKAFI JAKAFI [Member] Represents information pertaining to JAKAFI (ruxolitinib), an oral Janus associate kinase (JAK) inhibitor sold within the United State of America. Document Period End Date Document Period End Date Schedule of Long-Lived Assets by Geographic Areas Long-Lived Assets by Geographic Areas [Table Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Income Taxes Income Tax Disclosure [Text Block] Diluted Net Income (Loss) Per Share Earnings Per Share, Diluted [Abstract] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Schedule of Net of Compensation Expense, Across the Net Assets Acquired Asset Acquisition [Table Text Block] 2024 Inducement Plan 2024 Inducement Plan [Member] 2024 Inducement Plan Shares acquired, average cost per share (in dollars per share) Shares Acquired, Average Cost Per Share Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] MINJUVI/MONJUVI MINJUVI/MONJUVI [Member] MINJUVI/MONJUVI Document Type Document Type Outstanding at the beginning of the period (in shares) Outstanding at the end of the period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Net Income (Loss) Per Share Earnings Per Share [Text Block] Name Outstanding Recovery, Individual Name Loss Contingencies [Table] Loss Contingencies [Table] Defined benefit pension gain, net of tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Office equipment Office Equipment [Member] Funding of future development costs (as a percent) License Agreement Percentage of Future Global Development Costs Funded Represents the percentage of future global development costs funded under the license agreement. Product and Service [Axis] Product and Service [Axis] Asset Acquisition [Domain] Asset Acquisition [Domain] Royalty payments on future global net sales (as a percent) Percentage Of Royalty Rate Payments Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized. Total revenues Revenue from Contract with Customer, Excluding Assessed Tax All Individuals All Individuals [Member] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Purchase price Payments to Acquire Property, Plant, and Equipment Cash and cash equivalents Asset Acquisition, Cash And Cash Equivalents Asset Acquisition, Cash And Cash Equivalents Asset acquisition, consideration transferred Asset Acquisition, Consideration Transferred Name Forgone Recovery, Individual Name Stock option grant term (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Total current assets Assets, Current Statistical Measurement [Axis] Statistical Measurement [Axis] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Loss contingency accrual Loss Contingency Accrual Commitment fee Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Share repurchase program, authorized, amount Share Repurchase Program, Authorized, Amount Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount CMHSL CMSHL [Member] CMSHL Tax withholdings related to restricted and performance share vesting Payment, Tax Withholding, Share-Based Payment Arrangement Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Basic net income (loss) Net Income (Loss) Available to Common Stockholders, Basic Marketable securities Asset Acquisition, Marketable Securities Asset Acquisition, Marketable Securities Accrued and Other Current Liabilities Accrued Liabilities, Current [Abstract] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] RSU and PSU Grant Price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Other comprehensive income (loss) Other comprehensive income (loss) Net other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Current liabilities: Liabilities, Current [Abstract] In-process research and development assets Indefinite-Lived Intangible Assets Acquired Geographical [Axis] Geographical [Axis] TABRECTA TABRECTA [Member] Represents information pertaining to TABRECTA, treatment of adult patients with metastatic NSCLC whose tumors have a mutation that leads to MET exon 14 skipping (METex14). Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Long-term line of credit Long-Term Line of Credit Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Accrued and other liabilities Increase (Decrease) in Accrued Liabilities Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Table] Diluted (in USD per share) Diluted net income (loss) per share ( in USD per share) Earnings Per Share, Diluted Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Title of 12(b) Security Title of 12(b) Security Uncured material breach, written notice period (in days) License Agreement, Written Notice Period For Uncured Material Breach License Agreement, Written Notice Period For Uncured Material Breach Accounts payable and accrued expenses Asset Acquisition, Accounts Payable And Accrued Expenses Asset Acquisition, Accounts Payable And Accrued Expenses Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] Net income per share Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items] Fungible ratio change adjustments (in shares) Share Based Compensation Arrangement by Share Based Payment Award, Number Of Shares Fungible Ratio Change Adjustments Share Based Compensation Arrangement by Share Based Payment Award, Shares Increase (Decrease) From Fungible Ratio Change Adjustments Net income (loss) per share: Earnings Per Share [Abstract] Earnings Per Share [Abstract] Debt instrument, variable rate floor (as percent) Debt Instrument, Variable Rate Floor Debt Instrument, Variable Rate Floor Asset Acquisition [Table] Asset Acquisition [Table] Schedule of Antidilutive Securities Excluded From the Diluted Net Computation of Earnings (Loss) Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Debt securities (government) Debt Securities, Available-for-Sale, Current Repurchases of Common Stock Repurchases of common stock Stock Repurchased and Retired During Period, Value Amortization of actuarial losses Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss) NIKTIMVO NIKTIMVO [Member] NIKTIMVO Long term equity investments Equity Securities, FV-NI, Noncurrent Sales allowances Provision for Loss on Contracts MacroGenics MacroGenics [Member] Represents details pertaining to MacroGenics with whom we have entered into an exclusive global collaboration and license agreement. Achievement of Milestone [Axis] Achievement of Milestone [Axis] Represents information by different categories of achievement of milestones. Income taxes paid Income Taxes Paid, Net Options exercised (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Milestone payment, estimated useful life (in years) License Agreement Milestone Payment, Useful Life License Agreement Milestone Payment, Useful Life Award Timing Disclosures [Line Items] Customer F Customer F [Member] Customer F Service cost Defined Benefit Plan, Service Cost Options granted (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Measurement Frequency [Domain] Measurement Frequency [Domain] Accrued compensation Employee-related Liabilities, Current Property and Equipment, net Property, Plant and Equipment Disclosure [Text Block] Unrealized gain on marketable securities, net of tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Steven Stein [Member] Steven Stein Other research and development Other Research and Development Expense Stockholders' Equity Equity [Text Block] Common stock held from investment (in shares) Investment Owned, Balance, Shares Net income (loss) Net income (loss) Net Income (Loss) Attributable to Parent Baker Entities Share Repurchase Program Baker Entities Share Repurchase Program [Member] Baker Entities Share Repurchase Program Expiration Date Trading Arrangement Expiration Date Construction in progress Construction in Progress [Member] Customer E Customer E [Member] Represents information pertaining to the customer E. Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Unrealized loss on long term investments Gain (loss) on equity investments Equity Securities, FV-NI, Unrealized Gain (Loss) Vesting period (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Amount recognized and received for the achievement of a predefined milestone License Agreement, Amount Recognized and Received for Achievement of a Predefined Milestone Represents the earning recognized and the payment received for the achievement of a predefined milestone under the license agreement. Property and equipment, net Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Repurchases of Common Stock Payments for Repurchase of Common Stock Adoption Date Trading Arrangement Adoption Date Base Rate Base Rate [Member] Merus Merus [Member] Represents information pertaining to Merus N. V. Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Accounts receivable Increase (Decrease) in Accounts Receivable Entity Current Reporting Status Entity Current Reporting Status Patrick Mayes [Member] Patrick Mayes Customer [Axis] Customer [Axis] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Income (loss) from operations Operating Income (Loss) Accumulated deficit Retained Earnings (Accumulated Deficit) Financial Instrument [Axis] Financial Instrument [Axis] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Executive Category: Executive Category [Axis] Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures License Agreements License Agreements License Agreements Finance lease liabilities Finance Lease, Liability, Current Current Fiscal Year End Date Current Fiscal Year End Date Average expected life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Subsequent Event Type Subsequent Event Type [Domain] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Payables and Accruals [Abstract] Payables and Accruals [Abstract] Beginning Balance (in shares) Ending Balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Other, net Other Nonoperating Income (Expense) Statement [Table] Statement [Table] Eli Lilly Eli Lilly Represents details pertaining to Eli Lilly with whom we have entered into a License, Development and Commercialization Agreement. Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Loss contingences, gross to net deduction (as percent) Loss Contingences, Gross To Net Deduction Percentage Loss Contingences, Gross To Net Deduction Percentage License Agreements License Agreements [Text Block] This element may be used to describe all significant license agreements of the reporting entity. Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Weighted-average fair value (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Variable Rate [Domain] Variable Rate [Domain] Maturities of marketable securities Proceeds from Sale and Maturity of Marketable Securities Finance lease liabilities Finance Lease, Liability, Noncurrent Outstanding stock options and awards (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Shares used in computing net income (loss) per share: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Roll forward of Level 3 liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] All Adjustments to Compensation All Adjustments to Compensation [Member] Share-based compensation arrangement by share-based payment award, equity instruments other than options and stock appreciation rights, impact on authorized share limitation (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options And Stock Appreciation Rights, Impact On Authorized Share Limitation Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options And Stock Appreciation Rights, Impact On Authorized Share Limitation Amendment Flag Amendment Flag Other current liabilities Asset Acquisition, Other Current Liabilities Asset Acquisition, Other Current Liabilities Termination Date Trading Arrangement Termination Date Net cash used in financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Escient Escient Pharmaceuticals [Member] Escient Pharmaceuticals Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Measure: Measure [Axis] Raw materials Inventory, Raw Materials, Net of Reserves Schedule of Option Activity Under the 2010 Stock Plan Share-Based Payment Arrangement, Option, Activity [Table Text Block] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Schedule of Fair Value of Assets Measured on Recurring Basis Fair Value, Assets Measured on Recurring Basis [Table Text Block] Basic (in shares) Weighted average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic (Profit) and loss sharing under collaboration agreements (Profit) and loss sharing under collaboration agreements Collaboration Loss (Profit) Sharing Expense Collaboration Loss (Profit) Sharing Expense Schedule of Calculation of Net Income (Loss) Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] OPZELURA OPZELURA [Member] Represents information pertaining to OPZELURA (ruxolitinib) cream, a novel cream formulation of Incyte's selective JAK1/JAK2 inhibitor ruxolitinib. Share Repurchase Program [Table] Share Repurchase Program [Table] Segment Reporting [Abstract] Cost of product revenues (including definite-lived intangible amortization) Cost of product revenues (including definite-lived intangible amortization) Cost of Revenue Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Average risk-free interest rates Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Regulatory Milestone Regulatory Milestone [Member] Regulatory Milestone Customer B Customer B [Member] Represents information pertaining to the customer B. Entity Tax Identification Number Entity Tax Identification Number Costs, expenses and other: Costs, expenses and other: Costs and Expenses [Abstract] Regulatory Milestones Regulatory Milestones Represents information pertaining to certain regulatory events on the basis of which certain milestones are achieved. Development Milestones Development Milestones Represents information pertaining to certain development events on the basis of which certain milestones are achieved. Asset Acquisition [Axis] Asset Acquisition [Axis] Weighted average price of options at the beginning of the period (in USD per share) Weighted average price of options at the end of the period (in USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Stock compensation Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Common stock, par value (in USD per share) Common Stock, Par or Stated Value Per Share Common stock, shares issued (in shares) Common Stock, Shares, Issued Payment to acquire license agreement Payments To Acquire License Agreement Payments To Acquire License Agreement ZYNYZ ZYNYZ [Member] ZYNYZ Use of Estimates Use of Estimates, Policy [Policy Text Block] Litigation settlement, amount awarded to other party Litigation Settlement, Amount Awarded to Other Party Interest expense Interest Expense, Nonoperating Trading Arrangement: Trading Arrangement [Axis] Total Shareholder Return Amount Total Shareholder Return Amount Loss Contingencies [Line Items] Loss Contingencies [Line Items] Change in fair value of contingent consideration Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Insider Trading Arrangements [Line Items] Security Exchange Name Security Exchange Name Options cancelled (in USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price JAKAVI Royalty Revenues JAKAVI Royalty Revenues [Member] Represents information pertaining to JAKAVI royalty revenues, an oral Janus associate kinase (JAK) inhibitor sold within the United State of America. Total liabilities Liabilities Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Unpaid purchases of property and equipment Capital Expenditures Incurred but Not yet Paid Aggregate principal amount Line of Credit Facility, Maximum Borrowing Capacity Marketable securities—available-for-sale (amortized cost $473,126 and $469,917 as of September 30, 2025 and December 31, 2024, respectively; allowance for credit losses $0 as of September 30, 2025 and December 31, 2024) Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Cash paid for contract dispute settlement Loss Contingency Accrual, Payments Stock repurchased (in shares) Stock Repurchased During Period, Shares Indefinite-Lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Other current liabilities Other Liabilities, Current Schedule of Concentration of Credit Risk Related to Collaborative Partners Schedules of Concentration of Risk by Risk Factor Related to Collaborative Partners [Table Text Block] Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark, related to the collaborative partners. Statement Statement [Line Items] Variable Rate [Axis] Variable Rate [Axis] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents Cash and Cash Equivalent Counterparty Name [Axis] Counterparty Name [Axis] Reportable Segment Reportable Segment [Member] Reportable Segment Additional authorization (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Customer A Customer A [Member] Represents information pertaining to the customer A. Deferred income taxes Increase (Decrease) in Deferred Income Taxes Common Stock Common Stock [Member] Consolidated leverage ratio Line Of Credit Facility Covenant Terms Consolidated Total Leverage Ratio Maximum Line Of Credit Facility Covenant Terms Consolidated Total Leverage Ratio Maximum MorphoSys AG MorphoSys AG [Member] Represents member information pertaining to MorphoSys AG. Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Non-NEOs Non-NEOs [Member] Novartis Novartis Represents details pertaining to Novartis with whom we have entered into a Collaboration and License Agreement. Net increase (decrease) in cash, cash equivalents, and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation